AcuityMD announced it has raised $80 million in new funding to expand its artificial intelligence platform for the medical technology industry, bringing its total funding to more than $160 million and valuing the company at $955 million. The Series C round was led by StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management.
The company’s platform is designed to help MedTech organizations navigate increasingly complex commercial environments by aggregating fragmented healthcare data into a unified system. AcuityMD integrates sources such as claims databases, FDA filings, government records, and market signals into a proprietary knowledge graph that maps relationships across physicians, facilities, procedures, and reimbursement dynamics.
Building on this foundation, AcuityMD has introduced AcuityAI, an AI capability that delivers context-aware insights tailored to commercial teams. The tool connects the company’s data model with customer-specific business context to help sales representatives and leaders identify opportunities, prioritize targets, and improve execution.
AcuityMD currently serves more than 400 MedTech companies, including 16 of the top 20 in the industry, and has helped customers identify over $34 billion in pipeline opportunities.
The new funding will be used to accelerate development of agentic AI capabilities for commercial roles, deepen the company’s MedTech ontology, and expand the platform beyond commercial functions to support the broader lifecycle of medical technology adoption.
As MedTech companies face shifting market dynamics driven by regulatory changes, hospital consolidation, and evolving reimbursement structures, AcuityMD aims to provide a centralized intelligence layer that improves decision-making and speeds time to market.
KEY QUOTES:
“AcuityMD is scaling rapidly while continuing to invest thoughtfully in its people and platform. The depth of the company’s data provides a meaningful advantage, and as AI capabilities continue to advance, that foundation becomes more valuable. We also see significant opportunities for AcuityMD to benefit the broader MedTech organization beyond commercial, reinforcing our decision to deepen our commitment.”
Hunter Somerville, Partner, StepStone Group
“AcuityAI has given our commercial team sharper answers, faster. Insights that used to take hours are now surfaced right when our reps need them, leading to richer conversations and opportunities we might otherwise have missed. One of our sales leaders asked AcuityAI for intel on a new national contract with a large health system, and quickly had a full business plan: where to go, which surgeons to prioritize, and more context than he could get spending hours on Google.”
Mark Edwards, Senior Director Of Sales Operations, Kuros Biosciences
“AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories, and the teams launching the next generation of innovation. I’m grateful to the hundreds of customers who have helped shape our platform. This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies.”
Mike Monovoukas, CEO And Co-Founder, AcuityMD
